Condition
Haemophilus Influenzae
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed3
Active Not Recruiting1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07743008Phase 2Active Not RecruitingPrimary
Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
NCT00814489Phase 1Completed
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
NCT00849069Phase 1TerminatedPrimary
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
NCT01730391Completed
Neisseria Meningitidis Burden of Disease Study
NCT00804284Completed
Database Surveillance Safety Study of PENTACEL® Vaccine
Showing all 5 trials